MedScien,
Journal Year:
2024,
Volume and Issue:
1(10)
Published: Dec. 31, 2024
This
paper
aims
to
explore
the
effect
of
anti-PD-L1
antibody
on
HCT116
colorectal
cancer
cells
and
their
corresponding
xenografts
in
a
mouse
model.
The
central
hypothesis
is
that
increasing
concentration
antibodies
duration
treatment
will
result
reduction
cell
viability,
tumour
size,
an
enhancement
T
activation.
viability
was
evaluated
through
MTT
method,
which
quantifies
metabolic
activity
as
indicator
cellular
health.
size
determined
by
weighing
excised
tumours.
An
enzyme-linked
immunosorbent
assay
(ELISA)
employed
evaluate
activation
quantifying
interleukin-2
(IL-2)
production.
In
order
establish
framework
for
comparison,
eriodictyol,
known
PD-L1
inhibitor,
used
positive
control,
while
unrelated
served
negative
control.
According
research,
preliminary
study
results
indicated
higher
concentrations
prolonged
exposure
significantly
reduced
weight,
IL-2
levels,
suggests
enhanced
These
indicate
strong
correlation
between
therapy
immune
system
involvement
context
cancer.
objective
this
emphasise
potential
stimulating
response
malignant
growths.
Furthermore,
necessity
optimising
parameters
investigated
disccussed,
including
dosage
duration,
maximise
efficacy
immunotherapy.
could
facilitate
use
checkpoint
inhibitors
clinical
settings,
potentially
improving
outcomes
patients
with
other
types.
Cancer Nanotechnology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Jan. 17, 2025
Emphasizing
the
significance
of
cancer-associated
fibroblasts
(CAFs),
non-malignant
yet
pivotal
players
within
tumor
microenvironment
(TME),
this
review
illuminates
role
inflammatory
subtype
(iCAF)
as
catalysts
in
cancer
proliferation,
metastasis,
and
therapeutic
resistance.
Given
their
paramount
importance,
targeting
CAFs
emerges
a
robust
strategy
evolving
landscape
immunotherapy.
Nanomaterials,
distinguished
by
unique
features
malleability,
hold
considerable
promise
biomedicine,
especially
precision-oriented
domain
therapy.
Their
aptitude
for
modulating
immune
responses,
amplifying
drug
efficacy
through
precise
delivery,
discerningly
focusing
on
cells
TME
situates
nanomaterials
formidable
tools
to
transcend
boundaries
set
conventional
treatments.
This
scrutinizes
convoluted
interplay
among
CAFs,
cells,
TME.
It
further
showcases
widely
utilized
management.
We
underscore
potential
nanoscale
delivery
systems
directed
at
underscoring
transformative
power
revolutionizing
therapies,
enhancing
precision,
culminating
improved
patient
outcomes.
Biomaterials Science,
Journal Year:
2024,
Volume and Issue:
12(16), P. 4045 - 4064
Published: Jan. 1, 2024
With
the
increasing
research
and
deepening
understanding
of
glioblastoma
(GBM)
tumour
microenvironment
(TME),
novel
more
effective
therapeutic
strategies
have
been
proposed.
The
GBM
TME
involves
intricate
interactions
between
non-tumour
cells,
promoting
progression.
Key
goals
for
treatment
include
improving
immunosuppressive
microenvironment,
enhancing
cytotoxicity
immune
cells
against
tumours,
inhibiting
growth
proliferation.
Consequently,
remodeling
using
nanotechnology
has
emerged
as
a
promising
approach.
Nanoparticle-based
drug
delivery
enables
targeted
delivery,
thereby
specificity,
facilitating
combination
therapies,
optimizing
metabolism.
This
review
provides
an
overview
discusses
methods
nanotechnology.
Specifically,
it
explores
application
in
ameliorating
cell
immunosuppression,
inducing
immunogenic
death,
stimulating,
recruiting
regulating
metabolism,
modulating
crosstalk
tumours
other
cells.
IGI Global eBooks,
Journal Year:
2025,
Volume and Issue:
unknown, P. 219 - 252
Published: April 25, 2025
The
intrinsic
immune
system
activity
awakens
and
trains
the
patient's
to
destroy
tumor
cells.
Immunotherapy
has
become
a
standard
method
for
treating
cancer
since
it
is
more
potent
secure
option
than
conventional
therapies
like
surgery,
radiotherapy,
chemotherapy.
Chimeric
antigen
receptor-modified
T
cells,
checkpoint
blockades,
vaccines
are
three
primary
forms
of
immunotherapy
that
have
been
developed
recently.
Chemotherapy,
radiation
therapy,
surgery
continue
be
mainstays
treatment
despite
decades
advancements.
Lung
cancer,
melanoma,
advanced
bladder,
kidney,
other
tumors
all
successfully
treated
with
immunotherapy.
used
cure
illnesses
by
regulating
an
overactive
or
underactive
system.
Biomaterials
efficiency
will
increased
help
engineering
targeted
drug
delivery.
Chapter
highlights
recent
advancement
in
tailored
biomaterials
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1181 - 1181
Published: Sept. 7, 2024
The
programmed
death-1/programmed
death-ligand
1
(PD-1/PD-L1)
immune
checkpoint
constitutes
an
inhibitory
pathway
best
known
for
its
regulation
of
cluster
differentiation
8
(CD8)+
T
cell-mediated
responses.
Engagement
PD-L1
with
PD-1
expressed
on
CD8+
cells
activates
downstream
signaling
pathways
that
culminate
in
cell
exhaustion
and/or
apoptosis.
Physiologically,
these
immunosuppressive
effects
exist
to
prevent
autoimmunity,
but
cancer
exploit
this
by
overexpressing
facilitate
escape.
Intravenously
(IV)
administered
inhibitors
(ICIs)
block
the
interaction
between
PD-1/PD-L1
have
achieved
great
success
reversing
and
promoting
tumor
regression
various
malignancies.
However,
ICIs
can
cause
immune-related
adverse
events
(irAEs)
due
off-tumor
toxicities
which
limits
their
therapeutic
potential.
Therefore,
considerable
effort
has
been
channeled
into
exploring
alternative
delivery
strategies
enhance
tumor-directed
reduce
irAEs.
Here,
we
briefly
describe
PD-1/PD-L1-targeted
immunotherapy
associated
We
then
provide
a
detailed
review
approaches,
including
locoregional
(LDD)-,
oncolytic
virus
(OV)-,
nanoparticle
(NP)-,
ultrasound
microbubble
(USMB)-mediated
are
currently
under
investigation
enhancing
tumor-specific
minimize
toxic
effects.
conclude
commentary
key
challenges
methods
potential
mitigate
them.
